Studie

A Phase 3, Open-label, Randomized, Multi-center, Controlled Trial to Evaluate the Pharmacokinetics and Pharmacodynamics of Edoxaban and to Compare the Efficacy and Safety of Edoxaban With Standard of Care Anticoagulant Therapy in Pediatric Subjects From B

Erkrankungsgruppe:

Begleittherapie

Organsystem:

Blut

Stadium:

Ersterkrankung

Standort:

Essen

EudraCT:

2016-000991-49

Prüfplan-Code:

DU176b-D-U312

Phase:

III

Prüfsubstanz:

Edoxaban, Fondaparinux

Sponsor:

Daiichi Sankyo, Inc.